SRR10899955
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.400
- E2F_TARGETS+0.300
- KRAS_SIGNALING_UP+0.300
- PANCREAS_BETA_CELLS+0.300
- PROTEIN_SECRETION+0.300
- ALLOGRAFT_REJECTION+0.200
- APOPTOSIS+0.200
- COMPLEMENT+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- IL2_STAT5_SIGNALING+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.300
- ADIPOGENESIS-0.200
- FATTY_ACID_METABOLISM-0.200
- GLYCOLYSIS-0.200
- OXIDATIVE_PHOSPHORYLATION-0.200
- BILE_ACID_METABOLISM-0.100
- CHOLESTEROL_HOMEOSTASIS-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- ESTROGEN_RESPONSE_LATE-0.100
- MYOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10899986 | — | — | 0.752 |
| 2 | SRR650191 | — | — | 0.708 |
| 3 | 8828489a-e6fd-43ca-9232-e1b759d6edcf | — | — | 0.704 |
| 4 | TCGA-D8-A1J8-01A-11R-A13Q-07 | — | B | 0.699 |
| 5 | TCGA-ZF-AA5H-01A-11R-A39I-07 | — | — | 0.698 |
| 6 | MNG215 | — | — | 0.697 |
| 7 | TCGA-E2-A15M-01A-11R-A12D-07 | — | A | 0.696 |
| 8 | TCGA-BH-A1FE-01A-11R-A13Q-07 | — | A | 0.685 |
| 9 | BS_J70GK8SM | Supratentorial Ependymoma | — | 0.682 |
| 10 | s0122319 | — | — | 0.681 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |